Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States
- PMID: 21444863
- PMCID: PMC4821471
- DOI: 10.1200/JCO.2010.31.9004
Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States
Abstract
Purpose: For patients who elect to have prostate cancer screening, the optimal time to discontinue screening is unknown. Our objective was to describe rates and predictors of prostate-specific antigen (PSA) screening among older men in the United States.
Methods: Data were extracted from the population-based 2000 and 2005 National Health Interview Survey (NHIS). PSA screening was defined as a PSA test as part of a routine exam within the past year. Demographic, socioeconomic, and functional characteristics were collected, and a validated 5-year estimated life expectancy was calculated. Age-specific rates of PSA screening were determined, and sampling weight-adjusted multivariate regressions were fitted to determine predictors of screening among men age 70 years or older.
Results: The PSA screening rate was 24.0% in men age 50 to 54 years, and it increased steadily with age until a peak of 45.5% among age 70 to 74 years. Screening rates then gradually declined by age, and 24.6% of men age 85 years or older reported being screened. Among men age 70 years or older, screening rates varied by estimated 5-year life expectancy: rates were 47.3% in men with high life expectancies (≤ 15% probability of 5-year mortality), 39.2% in men with intermediate life expectancies (16% to 48% probability), and 30.7% in men with low life expectancies (> 48% probability; P < .001). In multivariate analysis, estimated life expectancy and age remained independently associated with PSA screening (P < .001 for each).
Conclusion: Rates of PSA screening in the United States are associated with age and estimated life expectancy, but excessive PSA screening in elderly men with limited life expectancies remains a significant problem. The merits and limitations of PSA should be discussed with all patients considering prostate cancer screening.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Comment in
-
Words of wisdom: Re: Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.Eur Urol. 2011 Aug;60(2):392. doi: 10.1016/j.eururo.2011.05.021. Eur Urol. 2011. PMID: 21703965 No abstract available.
Similar articles
-
Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy.J Gen Intern Med. 2012 Jun;27(6):653-60. doi: 10.1007/s11606-011-1945-9. Epub 2011 Dec 17. J Gen Intern Med. 2012. PMID: 22180196 Free PMC article.
-
Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.JAMA Intern Med. 2016 May 1;176(5):654-61. doi: 10.1001/jamainternmed.2016.0695. JAMA Intern Med. 2016. PMID: 27042937 Free PMC article.
-
National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.J Clin Oncol. 2015 Aug 1;33(22):2416-23. doi: 10.1200/JCO.2015.61.6532. Epub 2015 Jun 8. J Clin Oncol. 2015. PMID: 26056181
-
Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.Ont Health Technol Assess Ser. 2015 May 1;15(11):1-37. eCollection 2015. Ont Health Technol Assess Ser. 2015. PMID: 26366237 Free PMC article. Review.
-
Screening for prostate cancer.Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Cochrane Database Syst Rev. 2013. PMID: 23440794 Free PMC article. Review.
Cited by
-
A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer.PLoS One. 2024 Feb 8;19(2):e0285745. doi: 10.1371/journal.pone.0285745. eCollection 2024. PLoS One. 2024. PMID: 38329970 Free PMC article.
-
Associations of Content and Context of Communication with Prostate-Specific Antigen Testing.Int J Environ Res Public Health. 2023 May 4;20(9):5721. doi: 10.3390/ijerph20095721. Int J Environ Res Public Health. 2023. PMID: 37174239 Free PMC article.
-
Use of the prostate-specific antigen (PSA) test in the United States for men age ≥65, 1999-2015: Implications for practice interventions.Cancer Rep (Hoboken). 2021 Aug;4(4):e1352. doi: 10.1002/cnr2.1352. Epub 2021 May 1. Cancer Rep (Hoboken). 2021. PMID: 33932150 Free PMC article.
-
Cancer Progress and Priorities: Prostate Cancer.Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):267-277. doi: 10.1158/1055-9965.EPI-19-0412. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 32024765 Free PMC article. No abstract available.
-
Prostate-specific antigen (PSA) screening rates and factors associated with screening in Eastern Canadian men: Findings from cross-sectional survey data.Can Urol Assoc J. 2020 Jul;14(7):E319-E327. doi: 10.5489/cuaj.6072. Can Urol Assoc J. 2020. PMID: 32017690 Free PMC article.
References
-
- Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen. Invest Urol. 1979;17:159–163. - PubMed
-
- Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–1161. - PubMed
-
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
